{"disease":{"id":"exon-44","name":"exon 44"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05670730","title":"Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Avidity Biosciences, Inc.","has_results":false},{"nct_id":"NCT06244082","title":"Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":39,"lead_sponsor_name":"Avidity Biosciences, Inc.","has_results":false},{"nct_id":"NCT05996003","title":"NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"NS Pharma, Inc.","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}